Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennelle C Hodge

Showing results (31-40 of 53) with videos related to

Pageof 6
Sort By:
Clinical Pharmacology and Therapeutics|May 12, 2025
Evaluation of CYP2C19 Clinical Decision Support Alerts to Guide P2Y<sub>12</sub> Inhibitor PrescribingAshley N Springer, Leah A Alicea, Yemi Gafari, et al.
Cancer Genetics|November 1, 2018
Assessing copy number aberrations and copy neutral loss of heterozygosity across the genome as best practice: An evidence based review of clinical utility from the cancer genomics consortium (CGC) working group for myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative neoplasmsRashmi Kanagal-Shamanna, Jennelle C Hodge, Tracy Tucker, et al.
Clinical Pharmacology and Therapeutics|August 22, 2024
Development of a Multifaceted Program for Pharmacogenetics Adoption at an Academic Medical Center: Practical Considerations and Lessons LearnedTyler Shugg, Emma M Tillman, Amy M Breman, et al.
The Journal of Molecular Diagnostics : JMD|June 24, 2023
Characterization of Reference Materials for CYP3A4 and CYP3A5: A (GeT-RM) Collaborative ProjectAndrea Gaedigk, Erin C Boone, Amy J Turner, et al.
Cancer Genetics|October 23, 2018
Assessing copy number abnormalities and copy-neutral loss-of-heterozygosity across the genome as best practice in diagnostic evaluation of acute myeloid leukemia: An evidence-based review from the cancer genomics consortium (CGC) myeloid neoplasms working groupXinjie Xu, Christine Bryke, Madina Sukhanova, et al.
Frontiers in Oncology|July 20, 2023
Computational pharmacogenotype extraction from clinical next-generation sequencingTyler Shugg, Reynold C Ly, Wilberforce Osei, et al.
Journal of the American Heart Association|September 8, 2023
A Multicenter Analysis of Abnormal Chromosomal Microarray Findings in Congenital Heart DiseaseBenjamin J Landis, Lindsey R Helvaty, Gabrielle C Geddes, et al.
Journal of Medical Genetics|January 22, 2013
Deletions in 16q24.2 are associated with autism spectrum disorder, intellectual disability and congenital renal malformationGregory Ryan Handrigan, David Chitayat, Anath C Lionel, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|January 16, 2019
Correction: A new microdeletion syndrome involving TBC1D24, ATP6V0C, and PDPK1 causes epilepsy, microcephaly, and developmental delayBettina E Mucha, Siddharth Banka, Norbert Fonya Ajeawung, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|September 25, 2018
A new microdeletion syndrome involving TBC1D24, ATP6V0C, and PDPK1 causes epilepsy, microcephaly, and developmental delayBettina E Mucha, Siddharth Banka, Norbert Fonya Ajeawung, et al.
Pageof 6

Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
Clinical Pharmacology and Therapeutics|May 12, 2025
Evaluation of CYP2C19 Clinical Decision Support Alerts to Guide P2Y<sub>12</sub> Inhibitor PrescribingAshley N Springer, Leah A Alicea, Yemi Gafari, et al.
Cancer Genetics|November 1, 2018
Assessing copy number aberrations and copy neutral loss of heterozygosity across the genome as best practice: An evidence based review of clinical utility from the cancer genomics consortium (CGC) working group for myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative neoplasmsRashmi Kanagal-Shamanna, Jennelle C Hodge, Tracy Tucker, et al.
Clinical Pharmacology and Therapeutics|August 22, 2024
Development of a Multifaceted Program for Pharmacogenetics Adoption at an Academic Medical Center: Practical Considerations and Lessons LearnedTyler Shugg, Emma M Tillman, Amy M Breman, et al.
The Journal of Molecular Diagnostics : JMD|June 24, 2023
Characterization of Reference Materials for CYP3A4 and CYP3A5: A (GeT-RM) Collaborative ProjectAndrea Gaedigk, Erin C Boone, Amy J Turner, et al.
Cancer Genetics|October 23, 2018
Assessing copy number abnormalities and copy-neutral loss-of-heterozygosity across the genome as best practice in diagnostic evaluation of acute myeloid leukemia: An evidence-based review from the cancer genomics consortium (CGC) myeloid neoplasms working groupXinjie Xu, Christine Bryke, Madina Sukhanova, et al.
Frontiers in Oncology|July 20, 2023
Computational pharmacogenotype extraction from clinical next-generation sequencingTyler Shugg, Reynold C Ly, Wilberforce Osei, et al.
Journal of the American Heart Association|September 8, 2023
A Multicenter Analysis of Abnormal Chromosomal Microarray Findings in Congenital Heart DiseaseBenjamin J Landis, Lindsey R Helvaty, Gabrielle C Geddes, et al.
Journal of Medical Genetics|January 22, 2013
Deletions in 16q24.2 are associated with autism spectrum disorder, intellectual disability and congenital renal malformationGregory Ryan Handrigan, David Chitayat, Anath C Lionel, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|January 16, 2019
Correction: A new microdeletion syndrome involving TBC1D24, ATP6V0C, and PDPK1 causes epilepsy, microcephaly, and developmental delayBettina E Mucha, Siddharth Banka, Norbert Fonya Ajeawung, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|September 25, 2018
A new microdeletion syndrome involving TBC1D24, ATP6V0C, and PDPK1 causes epilepsy, microcephaly, and developmental delayBettina E Mucha, Siddharth Banka, Norbert Fonya Ajeawung, et al.
Pageof 6